Impact of treatment end point definitions on perceived differences in long-term outcome with tyrosine kinase inhibitor therapy in chronic myeloid leukemia

Hagop Kantarjian, Susan O'Brien, Elias Jabbour, Jenny Shan, Farhad Ravandi, Tapan Kadia, Stefan Faderl, Guillermo Garcia-Manero, Gautam Borthakur, Jorge Cortes

Research output: Contribution to journalArticle

Abstract

Purpose: Different definitions of progression-free survival (PFS) and event-free survival (EFS) may result in perceived differences in outcomes with tyrosine kinase inhibitor (TKI) therapies in chronic myelogenous leukemia (CML). Patients and Methods: We analyzed the outcome of 435 patients with early chronic-phase, Philadelphia chromosome-positive CML treated with imatinib (n = 281), nilotinib (n = 78), and dasatinib (n = 76) using definitions of PFS and EFS used in the International Randomized Study of Interferon Versus STI571 (IRIS), Evaluating Nilotinib Efficacy and Safety in Clinical Trials-Newly Diagnosed Patients (ENEST-nd), Dasatinib Versus Imatinib Study in Treatment-Naïve CML Patients (DASISION), and MD Anderson Cancer Center (MDACC) trials. Definitions for EFS-IRIS, time without progression in ENEST-nd, PFS-DASISION, and EFS-MDACC were as previously reported. The EFS-MDACC considered an event any instance of toxicity or death from any cause on or off therapy (if not counted before death as progression/event). Results: Of the 435 patients, 123 (28%) were taken off TKI therapy (resistance/loss of response, n = 33; blastic phase on TKI therapy, n = 6; intolerance/toxicity, n = 29; other causes, n = 55). Thirty-three patients (7.6%) have died; eight patients died on TKI therapy, two patients died within 60 days of being off TKIs, and 23 patients died after being off TKIs for more than 60 days. Of the 33 deaths, 19 deaths (eight deaths on TKI, two deaths within 60 days, and nine deaths off for resistance/relapse/transformation) would be counted as progression/events on the IRIS/ENEST-nd/DASISION studies, whereas 14 deaths would be censored at time off TKI. On the basis of the four definitions used by IRIS, ENEST-nd, DASISION, and MDACC trials, the corresponding 5-year PFS/EFS rates were 96%, 90%, 89%, and 81%. Conclusion: Uniform definitions of PFS and EFS are needed to compare the long-term efficacy and potential use of different TKIs in CML.

Original languageEnglish (US)
Pages (from-to)3173-3178
Number of pages6
JournalJournal of Clinical Oncology
Volume29
Issue number23
DOIs
StatePublished - Aug 10 2011
Externally publishedYes

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Protein-Tyrosine Kinases
Disease-Free Survival
Interferons
Therapeutics
Clinical Trials
Safety
Neoplasms
Philadelphia Chromosome
Imatinib Mesylate
Cause of Death
Survival Rate
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide
Recurrence

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Impact of treatment end point definitions on perceived differences in long-term outcome with tyrosine kinase inhibitor therapy in chronic myeloid leukemia. / Kantarjian, Hagop; O'Brien, Susan; Jabbour, Elias; Shan, Jenny; Ravandi, Farhad; Kadia, Tapan; Faderl, Stefan; Garcia-Manero, Guillermo; Borthakur, Gautam; Cortes, Jorge.

In: Journal of Clinical Oncology, Vol. 29, No. 23, 10.08.2011, p. 3173-3178.

Research output: Contribution to journalArticle

Kantarjian, H, O'Brien, S, Jabbour, E, Shan, J, Ravandi, F, Kadia, T, Faderl, S, Garcia-Manero, G, Borthakur, G & Cortes, J 2011, 'Impact of treatment end point definitions on perceived differences in long-term outcome with tyrosine kinase inhibitor therapy in chronic myeloid leukemia', Journal of Clinical Oncology, vol. 29, no. 23, pp. 3173-3178. https://doi.org/10.1200/JCO.2010.33.4169
Kantarjian, Hagop ; O'Brien, Susan ; Jabbour, Elias ; Shan, Jenny ; Ravandi, Farhad ; Kadia, Tapan ; Faderl, Stefan ; Garcia-Manero, Guillermo ; Borthakur, Gautam ; Cortes, Jorge. / Impact of treatment end point definitions on perceived differences in long-term outcome with tyrosine kinase inhibitor therapy in chronic myeloid leukemia. In: Journal of Clinical Oncology. 2011 ; Vol. 29, No. 23. pp. 3173-3178.
@article{652f15fdab6941bdbd748d7287b5f4b7,
title = "Impact of treatment end point definitions on perceived differences in long-term outcome with tyrosine kinase inhibitor therapy in chronic myeloid leukemia",
abstract = "Purpose: Different definitions of progression-free survival (PFS) and event-free survival (EFS) may result in perceived differences in outcomes with tyrosine kinase inhibitor (TKI) therapies in chronic myelogenous leukemia (CML). Patients and Methods: We analyzed the outcome of 435 patients with early chronic-phase, Philadelphia chromosome-positive CML treated with imatinib (n = 281), nilotinib (n = 78), and dasatinib (n = 76) using definitions of PFS and EFS used in the International Randomized Study of Interferon Versus STI571 (IRIS), Evaluating Nilotinib Efficacy and Safety in Clinical Trials-Newly Diagnosed Patients (ENEST-nd), Dasatinib Versus Imatinib Study in Treatment-Na{\"i}ve CML Patients (DASISION), and MD Anderson Cancer Center (MDACC) trials. Definitions for EFS-IRIS, time without progression in ENEST-nd, PFS-DASISION, and EFS-MDACC were as previously reported. The EFS-MDACC considered an event any instance of toxicity or death from any cause on or off therapy (if not counted before death as progression/event). Results: Of the 435 patients, 123 (28{\%}) were taken off TKI therapy (resistance/loss of response, n = 33; blastic phase on TKI therapy, n = 6; intolerance/toxicity, n = 29; other causes, n = 55). Thirty-three patients (7.6{\%}) have died; eight patients died on TKI therapy, two patients died within 60 days of being off TKIs, and 23 patients died after being off TKIs for more than 60 days. Of the 33 deaths, 19 deaths (eight deaths on TKI, two deaths within 60 days, and nine deaths off for resistance/relapse/transformation) would be counted as progression/events on the IRIS/ENEST-nd/DASISION studies, whereas 14 deaths would be censored at time off TKI. On the basis of the four definitions used by IRIS, ENEST-nd, DASISION, and MDACC trials, the corresponding 5-year PFS/EFS rates were 96{\%}, 90{\%}, 89{\%}, and 81{\%}. Conclusion: Uniform definitions of PFS and EFS are needed to compare the long-term efficacy and potential use of different TKIs in CML.",
author = "Hagop Kantarjian and Susan O'Brien and Elias Jabbour and Jenny Shan and Farhad Ravandi and Tapan Kadia and Stefan Faderl and Guillermo Garcia-Manero and Gautam Borthakur and Jorge Cortes",
year = "2011",
month = "8",
day = "10",
doi = "10.1200/JCO.2010.33.4169",
language = "English (US)",
volume = "29",
pages = "3173--3178",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "23",

}

TY - JOUR

T1 - Impact of treatment end point definitions on perceived differences in long-term outcome with tyrosine kinase inhibitor therapy in chronic myeloid leukemia

AU - Kantarjian, Hagop

AU - O'Brien, Susan

AU - Jabbour, Elias

AU - Shan, Jenny

AU - Ravandi, Farhad

AU - Kadia, Tapan

AU - Faderl, Stefan

AU - Garcia-Manero, Guillermo

AU - Borthakur, Gautam

AU - Cortes, Jorge

PY - 2011/8/10

Y1 - 2011/8/10

N2 - Purpose: Different definitions of progression-free survival (PFS) and event-free survival (EFS) may result in perceived differences in outcomes with tyrosine kinase inhibitor (TKI) therapies in chronic myelogenous leukemia (CML). Patients and Methods: We analyzed the outcome of 435 patients with early chronic-phase, Philadelphia chromosome-positive CML treated with imatinib (n = 281), nilotinib (n = 78), and dasatinib (n = 76) using definitions of PFS and EFS used in the International Randomized Study of Interferon Versus STI571 (IRIS), Evaluating Nilotinib Efficacy and Safety in Clinical Trials-Newly Diagnosed Patients (ENEST-nd), Dasatinib Versus Imatinib Study in Treatment-Naïve CML Patients (DASISION), and MD Anderson Cancer Center (MDACC) trials. Definitions for EFS-IRIS, time without progression in ENEST-nd, PFS-DASISION, and EFS-MDACC were as previously reported. The EFS-MDACC considered an event any instance of toxicity or death from any cause on or off therapy (if not counted before death as progression/event). Results: Of the 435 patients, 123 (28%) were taken off TKI therapy (resistance/loss of response, n = 33; blastic phase on TKI therapy, n = 6; intolerance/toxicity, n = 29; other causes, n = 55). Thirty-three patients (7.6%) have died; eight patients died on TKI therapy, two patients died within 60 days of being off TKIs, and 23 patients died after being off TKIs for more than 60 days. Of the 33 deaths, 19 deaths (eight deaths on TKI, two deaths within 60 days, and nine deaths off for resistance/relapse/transformation) would be counted as progression/events on the IRIS/ENEST-nd/DASISION studies, whereas 14 deaths would be censored at time off TKI. On the basis of the four definitions used by IRIS, ENEST-nd, DASISION, and MDACC trials, the corresponding 5-year PFS/EFS rates were 96%, 90%, 89%, and 81%. Conclusion: Uniform definitions of PFS and EFS are needed to compare the long-term efficacy and potential use of different TKIs in CML.

AB - Purpose: Different definitions of progression-free survival (PFS) and event-free survival (EFS) may result in perceived differences in outcomes with tyrosine kinase inhibitor (TKI) therapies in chronic myelogenous leukemia (CML). Patients and Methods: We analyzed the outcome of 435 patients with early chronic-phase, Philadelphia chromosome-positive CML treated with imatinib (n = 281), nilotinib (n = 78), and dasatinib (n = 76) using definitions of PFS and EFS used in the International Randomized Study of Interferon Versus STI571 (IRIS), Evaluating Nilotinib Efficacy and Safety in Clinical Trials-Newly Diagnosed Patients (ENEST-nd), Dasatinib Versus Imatinib Study in Treatment-Naïve CML Patients (DASISION), and MD Anderson Cancer Center (MDACC) trials. Definitions for EFS-IRIS, time without progression in ENEST-nd, PFS-DASISION, and EFS-MDACC were as previously reported. The EFS-MDACC considered an event any instance of toxicity or death from any cause on or off therapy (if not counted before death as progression/event). Results: Of the 435 patients, 123 (28%) were taken off TKI therapy (resistance/loss of response, n = 33; blastic phase on TKI therapy, n = 6; intolerance/toxicity, n = 29; other causes, n = 55). Thirty-three patients (7.6%) have died; eight patients died on TKI therapy, two patients died within 60 days of being off TKIs, and 23 patients died after being off TKIs for more than 60 days. Of the 33 deaths, 19 deaths (eight deaths on TKI, two deaths within 60 days, and nine deaths off for resistance/relapse/transformation) would be counted as progression/events on the IRIS/ENEST-nd/DASISION studies, whereas 14 deaths would be censored at time off TKI. On the basis of the four definitions used by IRIS, ENEST-nd, DASISION, and MDACC trials, the corresponding 5-year PFS/EFS rates were 96%, 90%, 89%, and 81%. Conclusion: Uniform definitions of PFS and EFS are needed to compare the long-term efficacy and potential use of different TKIs in CML.

UR - http://www.scopus.com/inward/record.url?scp=80051821734&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80051821734&partnerID=8YFLogxK

U2 - 10.1200/JCO.2010.33.4169

DO - 10.1200/JCO.2010.33.4169

M3 - Article

C2 - 21747082

AN - SCOPUS:80051821734

VL - 29

SP - 3173

EP - 3178

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 23

ER -